ProJect Pharmaceutics receives CIR application renewal (Research Tax Credit) for the benefit of its French customers towards 2025

ProJect Pharmaceutics is a contract research and development organization (CRO) specialized in formulation and process development for parenteral drug products. Expanding the offering of its service portfolio towards the French customer base, ProJect Pharmaceutics was engaged to apply at the French Ministère de L’Enseignement Supérieur, De La Recherche Et De L’Innovation for eligibility to join the French tax credit for research program (Credit d’Impôt Recherche, CIR). After successful approval for the previous years, we are proud to have again received the renewal of CIR application through 2025. We are delighted to continue to offer such big benefit to our French customers once they enter into a collaboration with ProJect Pharmaceutics.